Contribution of genetic and dietary insulin resistance to Alzheimer phenotype in APP/PS1 transgenic mice

Journal of Cellular and Molecular Medicine

Volumn 16, Issue 6, 2012, Pages 1206-1222

  Hiltunen, Mikko ^a   Khandelwal, Vinoth K M ^a   Yaluri, Nagendra ^a   Tiilikainen, Tea ^a   Tusa, Maija ^a,b   Koivisto, Henna ^a   Krzisch, Marine ^a   Vepsäläinen, Saila ^a   Mäkinen, Petra ^a   Kemppainen, Susanna ^a   Miettinen, Pasi ^a   Haapasalo, Annakaisa ^a   Soininen, Hilkka ^a,b   Laakso, Markku ^a,b   Tanila, Heikki ^a,b  

^a UNIVERSITY OF EASTERN FINLAND   (Finland)

^b KUOPIO UNIVERSITY HOSPITAL   (Finland)

Author keywords

amyloid; Alzheimer's disease; Hyperinsulinaemia; Insulin growth factor 2; Insulin resistance; Type 2 diabetes mellitus

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID PRECURSOR PROTEIN; GLYCOGEN SYNTHASE KINASE 3; GLYCOGEN SYNTHASE KINASE 3 BETA; INSULIN; PRESENILIN 1; SOMATOMEDIN B;

ALZHEIMER DISEASE; ANIMAL; ARTICLE; BLOOD; BRAIN; BRAIN CORTEX; FEMALE; GENETICS; GLUCOSE TOLERANCE TEST; HYBRIDIZATION; HYPERGLYCEMIA; INSULIN RESISTANCE; LIPID DIET; MALE; METABOLISM; MOUSE; PATHOLOGY; PHENOTYPE; PHOSPHORYLATION; SIGNAL TRANSDUCTION; TRANSGENIC MOUSE; WESTERN BLOTTING;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; AMYLOID BETA-PROTEIN PRECURSOR; ANIMALS; BLOTTING, WESTERN; BRAIN; CEREBRAL CORTEX; DIET, HIGH-FAT; FEMALE; GLUCOSE TOLERANCE TEST; GLYCOGEN SYNTHASE KINASE 3; HYBRIDIZATION, GENETIC; HYPERGLYCEMIA; INSULIN; INSULIN RESISTANCE; INSULIN-LIKE GROWTH FACTOR II; MALE; MICE; MICE, TRANSGENIC; PHENOTYPE; PHOSPHORYLATION; PRESENILIN-1; SIGNAL TRANSDUCTION;

MUS; MUS MUSCULUS;

EID: 84861553118     PISSN: 15821838     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1582-4934.2011.01384.x     Document Type: Article

References (33)

1. Janson J, Laedtke T, Parisi JE, et al. Increased risk of type 2 diabetes in Alzheimer disease. Diabetes. 2004; 53: 474-81.
2. Luchsinger JA, Tang MX, Shea S, et al. Hyperinsulinemia and risk of Alzheimer disease. Neurology. 2004; 63: 1187-92.
3. Vanhanen M, Soininen H. Glucose intolerance, cognitive impairment and Alzheimer's disease. Curr Opin Neurol. 1998; 11: 673-7.
4. Irie F, Fitzpatrick AL, Lopez OL, et al. Enhanced risk for Alzheimer disease in persons with type 2 diabetes and APOE epsilon4: the Cardiovascular Health Study Cognition Study. Arch Neurol. 2008; 65: 89-93.
5. Ronnemaa E, Zethelius B, Sundelof J, et al. Impaired insulin secretion increases the risk of Alzheimer disease. Neurology. 2008; 71: 1065-71.
6. Xu WL, von Strauss E, Qiu CX, et al. Uncontrolled diabetes increases the risk of Alzheimer's disease: a population-based cohort study. Diabetologia. 2009; 52: 1031-9.
7. Ahtiluoto S, Polvikoski T, Peltonen M, et al. Diabetes, Alzheimer disease, and vascular dementia: a population-based neuropathologic study. Neurology. 2010; 75: 1195-202.
8. Cannon CP. Mixed dyslipidemia, metabolic syndrome, diabetes mellitus, and cardiovascular disease: clinical implications. Am J Cardiol. 2008; 102: 5L-9L.
9. Matsuzaki T, Sasaki K, Tanizaki Y, et al. Insulin resistance is associated with the pathology of Alzheimer disease: the Hisayama study. Neurology. 2010; 75: 764-70.
10. Alafuzoff I, Aho L, Helisalmi S, et al. Beta-amyloid deposition in brains of subjects with diabetes. Neuropathol Appl Neurobiol. 2009; 35: 60-8.
11. Vekrellis K, Ye Z, Qiu WQ, et al. Neurons regulate extracellular levels of amyloid beta-protein via proteolysis by insulin-degrading enzyme. J Neurosci. 2000; 20: 1657-65.
12. Gasparini L, Xu H. Potential roles of insulin and IGF-1 in Alzheimer's disease. Trends Neurosci. 2003; 26: 404-6.
13. Craft S. Insulin resistance and Alzheimer's disease pathogenesis: potential mechanisms and implications for treatment. Curr Alzheimer Res. 2007; 4: 147-52.
14. Jope RS, Johnson GV. The glamour and gloom of glycogen synthase kinase-3. Trends Biochem Sci. 2004; 29: 95-102.
15. Phiel CJ, Wilson CA, Lee VM, et al. GSK-3alpha regulates production of Alzheimer's disease amyloid-beta peptides. Nature. 2003; 423: 435-9.
16. Ho L, Qin W, Pompl PN, et al. Diet-induced insulin resistance promotes amyloidosis in a transgenic mouse model of Alzheimer's disease. FASEB J. 2004; 18: 902-4.
17. Freude S, Hettich MM, Schumann C, et al. Neuronal IGF-1 resistance reduces Abeta accumulation and protects against premature death in a model of Alzheimer's disease. FASEB J. 2009; 23: 3315-24.
18. Takeda S, Sato N, Uchio-Yamada K, et al. Diabetes-accelerated memory dysfunction via cerebrovascular inflammation and Abeta deposition in an Alzheimer mouse model with diabetes. Proc Natl Acad Sci U S A. 2010; 107: 7036-41.
19. Jankowsky JL, Fadale DJ, Anderson J, et al. Mutant presenilins specifically elevate the levels of the 42 residue beta-amyloid peptide in vivo: evidence for augmentation of a 42-specific gamma secretase. Hum Mol Genet. 2004; 13: 159-70.
20. Devedjian JC, George M, Casellas A, et al. Transgenic mice overexpressing insulin-like growth factor-II in beta cells develop type 2 diabetes. J Clin Invest. 2000; 105: 731-40.
21. Lacy PE, Kostianovsky M. Method for the isolation of intact islets of Langerhans from the rat pancreas. Diabetes. 1967; 16: 35-9.
22. Takuma H, Arawaka S, Mori H. Isoforms changes of tau protein during development in various species. Brain Res Dev Brain Res. 2003; 142: 121-7.
23. Ma QL, Yang F, Rosario ER, et al. Beta-amyloid oligomers induce phosphorylation of tau and inactivation of insulin receptor substrate via c-Jun N-terminal kinase signaling: suppression by omega-3 fatty acids and curcumin. J Neurosci. 2009; 29: 9078-89.
24. Dalessandris C, Lauro R, Presta I, et al. C-reactive protein induces phosphorylation of insulin receptor substrate-1 on Ser307 and Ser 612 in L6 myocytes, thereby impairing the insulin signalling pathway that promotes glucose transport. Diabetologia. 2007; 50: 840-9.
25. Julien C, Tremblay C, Phivilay A, et al. High-fat diet aggravates amyloid-beta and tau pathologies in the 3xTg-AD mouse model. Neurobiol Aging. 2010; 31: 1516-31.
26. Rahman A, Akterin S, Flores-Morales A, et al. High cholesterol diet induces tau hyperphosphorylation in apolipoprotein E deficient mice. FEBS Lett. 2005; 579: 6411-6.
27. Reger MA, Watson GS, Green PS, et al. Intranasal insulin improves cognition and modulates beta-amyloid in early AD. Neurology. 2008; 70: 440-8.
28. Calhoun ME, Burgermeister P, Phinney AL, et al. Neuronal overexpression of mutant amyloid precursor protein results in prominent deposition of cerebrovascular amyloid. Proc Natl Acad Sci U S A. 1999; 96: 14088-93.
29. Shino A, Matsuo T, Iwatsuka H, et al. Structural changes of pancreatic islets in genetically obese rats. Diabetologia. 1973; 9: 413-21.
30. Duffy KR, Pardridge WM, Rosenfeld RG. Human blood-brain barrier insulin-like growth factor receptor. Metabolism. 1988; 37: 136-40.
31. Chen DY, Stern SA, Garcia-Osta A, et al. A critical role for IGF-II in memory consolidation and enhancement. Nature. 2011; 469: 491-7.
32. Stein TD, Johnson JA. Lack of neurodegeneration in transgenic mice overexpressing mutant amyloid precursor protein is associated with increased levels of transthyretin and the activation of cell survival pathways. J Neurosci. 2002; 22: 7380-8.
33. Stein TD, Anders NJ, DeCarli C, et al. Neutralization of transthyretin reverses the neuroprotective effects of secreted amyloid precursor protein (APP) in APPSW mice resulting in tau phosphorylation and loss of hippocampal neurons: support for the amyloid hypothesis. J Neurosci. 2004; 24: 7707-17.